This monetization will enhance Royalty Pharma's balance sheet and allow for a disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions. The ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare ...

Under a royalty monetization agreement finalized in December 2024, Idorsia received a USD 30 million payment from the R-Bridge Healthcare Fund in exchange for the rights to receive future AGAMREE ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash.